

Pro Pharmaceuticals Group Pty LTD ABN: 20 605 457 430 www.propg.com.au

Dear Healthcare Professional,

Shortage of OZEMPIC 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen

The Australian registered medicine, OZEMPIC 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 315107 Active ingredients: Semaglutide Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd is currently in shortage.

Pro Pharmaceuticals Group has arranged for the supply of an alternative product, **Ozempic 1 mg solution for injection pre-filled pen (Croatia).** This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until **31**st **March 2023** for the following indication(s):

Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.

Ozempic 1 mg solution for injection pre-filled pen (Croatia) is registered and marketed in Croatia by Novo Nordisk A/S, and therefore all labelling is in Croatian

<u>Pro Pharmaceuticals Group recommends that healthcare professionals refer to the Australian approved Product Information for recommended dosing for various indications.</u>

Reporting suspected adverse events is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **Ozempic 1 mg solution for injection pre-filled pen (Croatia)** must be reported by healthcare professionals, pharmacists and patients to the TGA at https://www.tga.gov.au/reporting-problems or to Pro Pharmaceuticals Group on 1300077674 or email regulatory@propg.com.au

Any product complaints with **Ozempic 1 mg solution for injection pre-filled pen (Croatia)** should be reported to Pro Pharmaceuticals Group on 1300 077674 or email regulatory@propg.com.au

Email: info@propg.com.au

For any orders please contact Pro Pharmaceuticals Group on 1300077674 or email info@propg.com.au

Please forward this information to relevant staff members in your organisation.

For further information, please contact Pro Pharmaceuticals Group on 1300077674 or email info@propg.com.au

Sincerely,
Sandip Manku – Director Pro Pharmaceuticals Group

P.O. Box 1016, Hampton North, Phone: 1300077674, Fax: +61(3)86790397